Trial Profile
A phase-I, open label clinical trial to assess the safety and tolerability of recombinant quadrivalent Human Papilloma Virus (qHPV) vaccine manufactured by Serum Institute of India Pvt.Ltd. in healthy adult volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2017
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Serum Institute of India (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Serum Institute of India
- 18 Jul 2017 Status changed from recruiting to completed.
- 23 Feb 2017 New trial record